Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: A randomised trial

Thorax

Volumn 65, Issue 1, 2010, Pages 51-56

  Minasian, C ^a   Wallis, C ^b   Metcalfe, C ^c   Bush, A ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DORNASE ALFA; MANNITOL; SALBUTAMOL; TERBUTALINE;

ADOLESCENT; ARTICLE; ASPERGILLUS FUMIGATUS; BRONCHOSPASM; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATION TEST; LUNG FIBROSIS; LUNG FUNCTION; MUCOLYSIS; NAUSEA; NEBULIZATION; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FUNCTION; SPUTUM CULTURE; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 73449118258     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2009.116970     Document Type: Article

References (30)

1. Fuchs H, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-42.
2. McCoy K, Hamilton S, Johnson CAC. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest 1996;153:1914-7.
3. Suri R, Metcalfe C, Lees B, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomized trial. Lancet 2001;353:1316-21.
4. Paul K, Rietschel E, Ballmann M, et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004;169:719-25.
5. Ranasinha C, Assoufi B, Shak S, et al. Efficacy and safety of short-term administration of aerosolized recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet 1993;342:199-202.
6. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998;95:1005-15.
7. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004;23:146-58.
8. Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 2007;261:5-16.
9. Boucher RC. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med 2007;13:231-40.
10. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354:241-50.
11. Elkins MR, Bye PT. Inhaled hypertonic saline as a therapy for cystic fibrosis. Curr Opin Pulm Med 2006;12:445-52.
12. Anderson SD, Brannan J, Spring J, et al. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med 1997;156:758-65.
13. Brannan JD, Anderson SD, Perry CP, et al. The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline. Respir Res 2005;6:144.
14. Barben J, Roberts M, Chew N, et al. Repeatability of bronchial responsiveness to mannitol dry powder in children with asthma. Pediatr Pulmonol 2003;36:490-4.
15. Daviskas E, Anderson SD, Brannan JD, et al. Inhalation of dry-powder mannitol increases mucociliary clearance. Eur Respir J 1997;10:2449-54.
16. Daviskas E, Anderson SD, Eberl S, et al. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 1999;159:1843-8.
17. Daviskas E, Anderson SD, Eberl S, et al. The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest 2001;119:414-21.
18. Robinson M, Daviskas E, Eberl S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999;14:678-85.
19. 1 in cystic fibrosis. Chest 2008;133:1388- 96.
20. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998;132:589-95.
21. American Thoracic Society. Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med 1995;152:1107-36.
22. Minasian C, Wallis C, Metcalfe C, et al. Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis. Pediatr Pulmonol 2008;43:1078-84.
23. Equi A, Balfour-Lynn IM, Bush A, et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360:978-84.
24. Southern KW, Smyth RL. Design of clinical trials in CF. Lancet 2003;361:349-50.
25. Equi A, Balfour-Lynn IM, Bush A, et al. Author's reply. Lancet 2003;361:350.
26. Rosenfeld M. An overview of endpoints for cystic fibrosis clinical trials: one size does not fit all. Proc Am Thorac Soc 2007;4:299-301.
27. Mayer-Hamblett N, Bamsey BW, Kronmal RA. Advancing cystic fibrosis measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc 2007;4:370-1.
28. Suri R, Metcalfe C, Wallis C, et al. Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respir Med 2007;101:254-60.
29. Quan JM, Tiddens HA, Sy JP, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001;139:813-20.
30. Daviskas E, Anderson SD, Eberl S, et al. Effects of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur Resp J 2008;31:765-72.